Aurobindo Pharma is pleased to announce that the company has received final approval from the US Food & Drug Administration ( USFDA) to manufacture and market Lamivudine and Zidovudine Tablets USP 1501300mg and is ready for launch.
Lamivudine and Zidovudine Tablets USP 150/300mg is the generic equivalent of VIV Healthcare Company’s Combivir® Tablets USP 1501300mg and is indicated as part of antiretroviral ( ARV) combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children. The annual sale of the product is approximately $265 million.
The product has been approved out of Unit VJJ (SEZ) formulations facility in Hyderabad, India Aurobindo now has a total of 150 ANDA approvals (122 Final approvals including I from Aurolife Pharma LLC and 28 Tentative approvals) from USFDA.
....more info
Lamivudine and Zidovudine Tablets USP 150/300mg is the generic equivalent of VIV Healthcare Company’s Combivir® Tablets USP 1501300mg and is indicated as part of antiretroviral ( ARV) combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children. The annual sale of the product is approximately $265 million.
The product has been approved out of Unit VJJ (SEZ) formulations facility in Hyderabad, India Aurobindo now has a total of 150 ANDA approvals (122 Final approvals including I from Aurolife Pharma LLC and 28 Tentative approvals) from USFDA.
....more info